L

Lord Weir of Ballyholme (DUP)

Speaking in the House of Lords on 3 June 2026

Debate

Alzheimer’s Disease: Diagnosis and Access to Experimental Drugs

Contribution

My Lords, early intervention can clearly be critical, but one of the barriers to early access, particularly to new drugs, is the current modelling of NICE. I think there is a level of criticism of its cost-benefit analysis in that sometimes it does not take sufficient cognisance of the health and economic impact, not simply on the person suffering from dementia but on the family and the carers, many of whom, for instance, are missing from work for long periods to care for their relatives. Will the Government commit to looking at that modelling to try to make sure that in the future the cost-benefit analysis is fit for purpose?

More from Lord Weir of Ballyholme (DUP)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

Partner sites